The U.S. Centers for Disease Control and Prevention (CDC) has revealed that the JN.1 variant of COVID-19 now constitutes over 60% of all cases in the United States. This represents a significant increase from the estimated prevalence of 44% just two weeks prior. The variant, more common among international travelers, is also dominating in Europe and experiencing a sharp rise in Asia. Despite its prevalence, the CDC notes that COVID-19 is causing severe disease less frequently than earlier in the pandemic.
The World Health Organization classified JN.1 as a “variant of interest” in December, but current evidence suggests a low risk to public health. The CDC emphasizes that there is no evidence indicating different symptoms for JN.1 compared to other variants. However, survey data from the UK shows some individuals reporting sleep issues and anxiety as potential symptoms.
While mask mandates are not being implemented widely in public places, certain hospitals in major cities, including Philadelphia and New York City, have reinstated masking requirements in response to the ongoing situation. The CDC continues to monitor and research the effects of COVID variants and will provide updates as new information emerges.